An Altered Maturation and Adhesion Phenotype of Dendritic Cells in Diseased Individuals Compared to Asymptomatic Carriers of Human T Cell Leukemia Virus Type 1
Restricted accessResearch articleFirst published online September, 2013
An Altered Maturation and Adhesion Phenotype of Dendritic Cells in Diseased Individuals Compared to Asymptomatic Carriers of Human T Cell Leukemia Virus Type 1
The immunopathogenic mechanisms underlying human T cell leukemia virus type 1 (HTLV-1)-mediated diseases such as adult T cell leukemia (ATL) and HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) are not clearly understood. As critical effectors of antiviral immune response, dendritic cells (DCs) are implicated to play an important role in determining the outcome of HTLV-1 infection. However, a complete understanding of their role in any disease pathogenesis requires extensive assessment of the phenotypic and functional state of DCs. To enable this, we developed a polychromatic antibody cocktail comprising key phenotypic and functional markers of DCs and applied it in a patient cohort from the HTLV-1 endemic region, Jamaica, consisted of seronegative controls, asymptomatic carriers (ACs), ATL, and HAM/TSP patients. This ex vivo analyses included two major subsets of blood DCs, myeloid and plasmacytoid (mDCs and pDCs, respectively). The comparative analyses of results demonstrated a decreased pDC frequency in both ATL and HAM/TSP patients as compared to ACs and seronegative controls. Similarly, CD86 expression on both mDCs and pDCs was significantly higher in HAM/TSP (but not ATL) patients compared to ACs. Interestingly, HLA-DR expression was significantly lower on pDCs of patients as compared to carriers; however, for mDCs, only the HAM/TSP group had significantly lower expression of HLA-DR. Unlike HAM/TSP individuals, ATL individuals had higher HLA-ABC expression on mDCs compared to ACs. Finally, both mDCs and pDCs of HAM/TSP patients had significantly higher expression of the programmed death ligand 1 (PD-L1) compared to ACs. Overall, this study suggests that DCs exhibit a differential phenotypic and functional profile between patients (ATL and HAM/TSP) and carriers of HTLV-1 and could provide an important tool for understanding HTLV-1 immunopathogenesis during infection and disease.
Get full access to this article
View all access options for this article.
References
1.
GoncalvesDU, ProiettiFA, RibasJGet al.Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev, 2010; 23,3:577–589.
2.
ProiettiFA, Carneiro-ProiettiAB, Catalan-SoaresBC, MurphyEL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene, 2005; 24,39:6058–6068.
3.
SonodaS, LiHC, TajimaK. Ethnoepidemiology of HTLV-1 related diseases: Ethnic determinants of HTLV-1 susceptibility and its worldwide dispersal. Cancer Sci, 2011; 102,2:295–301.
4.
MacatoniaSE, CruickshankJK, RudgeP, KnightSC. Dendritic cells from patients with tropical spastic paraparesis are infected with HTLV-1 and stimulate autologous lymphocyte proliferation. AIDS Res Hum Retroviruses, 1992; 8,9:1699–1706.
5.
JainP, ManuelSL, KhanZK, AhujaJ, QuannK, WigdahlB. DC-SIGN mediates cell-free infection and transmission of human T-cell lymphotropic virus type 1 by dendritic cells. J Virol, 2009; 83,21:10908–10921.
6.
ManuelSL, SchellTD, AcheampongE, RahmanS, KhanZK, JainP. Presentation of human T cell leukemia virus type 1 (HTLV-1) Tax protein by dendritic cells: The underlying mechanism of HTLV-1-associated neuroinflammatory disease. J Leukoc Biol, 2009; 86,5:1205–1216.
7.
JonesKS, Petrow-SadowskiC, HuangYK, BertoletteDC, RuscettiFW. Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat Med, 2008; 14,4:429–436.
8.
AhujaJ, KampaniK, DattaS, WigdahlB, FlaigKE, JainP. Use of human antigen presenting cell gene array profiling to examine the effect of human T-cell leukemia virus type 1 Tax on primary human dendritic cells. J Neurovirol, 2006; 12,1:47–59.
9.
AhujaJ, LepoutreV, WigdahlB, KhanZK, JainP. Induction of pro-inflammatory cytokines by human T-cell leukemia virus type-1 Tax protein as determined by multiplexed cytokine protein array analyses of human dendritic cells. Biomed Pharmacother, 2007; 61,4:201–208.
10.
JainP, AhujaJ, KhanZKet al.Modulation of dendritic cell maturation and function by the Tax protein of human T cell leukemia virus type 1. J Leukoc Biol, 2007; 82,1:44–56.
11.
MostollerK, NorburyCC, JainP, WigdahlB. Human T-cell leukemia virus type I Tax induces the expression of dendritic cell markers associated with maturation and activation. J Neurovirol, 2004; 10,6:358–371.
12.
RahmanS, KhanZK, WigdahlB, JenningsSR, TangyF, JainP. Murine FLT3 ligand-derived dendritic cell-mediated early immune responses are critical to controlling cell-free human T cell leukemia virus type 1 infection. J Immunol, 2011; 186,1:390–402.
13.
RahmanS, ManuelSL, KhanZKet al.Depletion of dendritic cells enhances susceptibility to cell-free infection of human T cell leukemia virus type 1 in CD11c-diphtheria toxin receptor transgenic mice. J Immunol, 2010; 184,10:5553–5561.
14.
AutissierP, SoulasC, BurdoTH, WilliamsKC. Evaluation of a 12-color flow cytometry panel to study lymphocyte, monocyte, and dendritic cell subsets in humans. Cytometry A, 2010; 77,5:410–419.
15.
FungE, EspositoL, ToddJA, WickerLS. Multiplexed immunophenotyping of human antigen-presenting cells in whole blood by polychromatic flow cytometry. Nat Protoc, 2010; 5,2:357–370.
16.
WangJC, KobieJJ, ZhangLet al.An 11-color flow cytometric assay for identifying, phenotyping, and assessing endocytic ability of peripheral blood dendritic cell subsets in a single platform. J Immunol Methods, 2009; 341,1–2:106–116.
17.
HaSJ, MuellerSN, WherryEJet al.Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med, 2008; 205,3:543–555.
18.
SakthivelP, GerekeM, BruderD. Therapeutic intervention in cancer and chronic viral infections: Antibody mediated manipulation of PD-1/PD-L1 interaction. Rev Recent Clin Trials, 2012; 7,1:10–23.
19.
FinnefrockAC, TangA, LiFet al.PD-1 blockade in rhesus macaques: Impact on chronic infection and prophylactic vaccination. J Immunol, 2009; 182,2:980–987.
20.
FreemanGJ, WherryEJ, AhmedR, SharpeAH. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med, 2006; 203,10:2223–2227.
21.
Dyavar ShettyR, VeluV, TitanjiKet al.PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J Clin Invest, 2012; 122,5:1712–1716.
22.
VeluV, TitanjiK, ZhuBet al.Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature, 2009; 458,7235:206–210.
23.
UrbaniS, AmadeiB, TolaDet al.Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatment. J Hepatol, 2008; 48,4:548–558.
24.
IkebuchiR, KonnaiS, ShiraiTet al.Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade. Vet Res, 2011; 42,1:103–117.
25.
ManuelSL, SehgalM, ConnollyJ, MakedonasG, KhanZK, GardnerJ, GoedertJ, BettsM, JainP. Lack of recall response to Tax in ATL and HAM/TSP patients but not in asymptomatic carriers of human T-cell leukemia virus type 1. J Clin Immunol, 2013(submitted).
26.
RoedererM. Spectral compensation for flow cytometry: Visualization artifacts, limitations, and caveats. Cytometry, 2001; 45,3:194–205.
27.
RoedererM, HardyRR. Frequency difference gating: A multivariate method for identifying subsets that differ between samples. Cytometry, 2001; 45,1:56–64.
28.
RoedererM, NozziJL, NasonMC. SPICE: Exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A, 2011; 79,2:167–174.
29.
DuesbergU, von dem BusscheA, KirschningC, MiyakeK, SauerbruchT, SpenglerU. Cell activation by synthetic lipopeptides of the hepatitis C virus (HCV)-core protein is mediated by toll like receptors (TLRs) 2 and 4. Immunol Lett, 2002; 84,2:89–95.
30.
AzakamiK, SatoT, ArayaNet al.Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders. Blood, 2009; 114,15:3208–3215.
31.
HishizawaM, ImadaK, KitawakiT, UedaM, KadowakiN, UchiyamaT. Depletion and impaired interferon-alpha-producing capacity of blood plasmacytoid dendritic cells in human T-cell leukaemia virus type I-infected individuals. Br J Haematol, 2004; 125,5:568–575.
32.
BestI, LopezG, VerdonckKet al.IFN-gamma production in response to Tax 161-233, and frequency of CD4+ Foxp3+ and Lin HLA-DRhigh CD123+ cells, discriminate HAM/TSP patients from asymptomatic HTLV-1-carriers in a Peruvian population. Immunology, 2009; 128,1 Suppl:e777–786.
33.
MeyersJH, JustementJS, HallahanCWet al.Impact of HIV on cell survival and antiviral activity of plasmacytoid dendritic cells. PLoS ONE, 2007; 2,5:e458.
34.
BrownKN, WijewardanaV, LiuX, Barratt-BoyesSM. Rapid influx and death of plasmacytoid dendritic cells in lymph nodes mediate depletion in acute simian immunodeficiency virus infection. PLoS Pathogens, 2009; 5,5:e1000413.
35.
NascimbeniM, PerieL, ChorroLet al.Plasmacytoid dendritic cells accumulate in spleens from chronically HIV-infected patients but barely participate in interferon-alpha expression. Blood, 2009; 113,24:6112–6119.
36.
FoussatA, Bouchet-DelbosL, BerrebiDet al.Deregulation of the expression of the fractalkine/fractalkine receptor complex in HIV-1-infected patients. Blood, 2001; 98,6:1678–1686.
Al-FahimA, CabreP, KastrukoffL, Dorovini-ZisK, OgerJ. Blood mononuclear cells in patients with HTLV-I-associated myelopathy: Lymphocytes are highly activated and adhesion to endothelial cells is increased. Cell Immunol, 1999; 198,1:1–10.
39.
WherryEJ. T cell exhaustion. Nat Immunol, 2011; 12,6:492–499.
40.
BlackburnSD, ShinH, HainingWNet al.Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol, 2009; 10,1:29–37.
41.
TrabattoniD, SaresellaM, BiasinMet al.B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood, 2003; 101,7:2514–2520.
42.
KozakoT, YoshimitsuM, FujiwaraHet al.PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia, 2009; 23,2:375–382.
43.
AbdelbaryNH, AbdullahHM, MatsuzakiTet al.Reduced Tim-3 expression on human T-lymphotropic virus type I (HTLV-I) Tax-specific cytotoxic T lymphocytes in HTLV-I infection. J Infect Dis, 2011; 203,7:948–959.
44.
SamimiS, BenoitB, EvansKet al.Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: Implications for immune suppression. Arch Dermatol, 2010; 146,12:1382–1388.
45.
TrautmannL, JanbazianL, ChomontNet al.Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med, 2006; 12,10:1198–1202.
46.
RadziewiczH, IbegbuC, FernandezMet al.Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol, 2007; 81:2545–2553.
47.
DayCL, KaufmannDE, KiepielaPet al.PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature, 2006; 443,7109:350–354.
48.
NakamotoN, ChoH, ShakedAet al.Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathogens, 2009; 5,2:e1000313.
49.
PennaA, PilliM, ZerbiniAet al.Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology, 2007; 45,3:588–601.
50.
BoniC, FisicaroP, ValdattaCet al.Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol, 2007; 81,8:4215–4225.
51.
BoettlerT, PantherE, BengschBet al.Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J Virol, 2006; 80,7:3532–3540.
52.
TopalianSL, HodiFS, BrahmerJRet al.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med, 2012; 366,26:2443–2454.
53.
BrahmerJR, TykodiSS, ChowLQet al.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med, 2012; 366,26:2455–2465.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
